ZymoGenetics News

FRANKLIN PARK, Ill.-- --Rubicon Technology, Inc. , a leading provider of sapphire substrates and products to the LED, RFIC, Semiconductor, and Optical industries, today rele... NEW PROVIDENCE, N.J.-- --Axion International Holdings, Inc.

ZymoGenetics Inc. said Monday it regained most of the marketing rights for its only marketed product, Recothrom, from partner Bayer Schering Pharma.

ZymoGenetics , the Seattle-based biotech company, said today in a regulatory filing that its drug to control excess surgical bleeding has received approval from Canadian regulators.

Bayer has withdrawn its application to market the ZymoGenetics drug Recothrom in Europe, the Seattle-based biotechnology company said Monday.

Puget Sound Business Journal Send this story to a friend Seattle biotechnology company ZymoGenetics Inc.

ZymoGenetics , the Seattle-based developer of a treatment to stop excess surgical bleeding, said today that its partner has voluntarily withdrawn an application to market the product in Europe.

Dendreon Grasps for $400M, ZymoGenetics Cuts 52 Jobs, Calistoga Advances at ASH, & More Seattle-Area Life Sciences News LUKE TIMMERMAN XCONOMY I groused last week that Seattle biotech news was slow, so naturally, this week I got swamped.

A federal judge in Tennessee has denied King Pharmaceuticals' requests for a preliminary injunction in its lawsuit against ZymoGenetics, the Seattle company said Thursday.

ZymoGenetics Inc. continued its transformation from a discovery engine to a development and sales organization, this time out-licensing its preclinical anti-IL21 antibody to former parent company Novo Nordisk A/S. Copenhagen, Denmark-based Novo Nordisk already owned ex-North American rights to the compound.

Companies mentioned in this article: ZymoGenetics, Inc. SEATTLE & COPENHAGEN -- -- Novo Nordisk A/S and ZymoGenetics, Inc.

Monrovia-based Xencor , a developer of biotherapeutics, said today that it has named Bruce Carter, Ph.D., most recently the Chief Executive Officer of ZymoGenetics, as Chairman of the firm's board of directors.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

Puget Sound Business Journal Bruce Carter, who headed Seattle biotech ZymoGenetics Inc.

A federal court in Tennessee has slapped ZymoGenetics Inc. with three temporary restraining orders related to a business dispute involving the drug Recothrom, the company disclosed Wednesday.

Main Category: Liver Disease / Hepatitis Also Included In: Clinical Trials / Drug Trials Article Date: 03 Nov 2009 Bristol-Myers Squibb Company and ZymoGenetics, Inc.

SUMMARY: Pegylated interferon lambda 1a , administered once-weekly or once every 2 weeks with or without daily ribavirin, demonstrated potent activity against hepatitis C virus in genotype 1 patients in a Phase 1b study to be presented this week at the 60th Annual Meeting of the American Association for the Study of Liver Diseases in Boston.

ZymoGenetics, Inc. today announced the initiation of a Phase 2 clinical trial of PEG-Interferon lambda and ribavirin in treatment-naive patients with chronic hepatitis C virus infection .

ZymoGenetics Inc. said Tuesday it started a midstage study on a potential hepatitis C treatment, triggering a $70 million payment from its partner, Bristol-Myers Squibb Co.

Xconomy.com -- One of the key people who transformed ZymoGenetics from a basic research institute into a more balanced biotech company with both R and D, has set up shop in a rival startup just a few blocks away on Seattlea s Eastlake Avenue.

MESA, Ariz.-- --B2 Digital, Inc. and Mob Candy Enterprises, Inc. announce the signing of a contract with Glen Meehan and Ur-Mee Entertainment for a national televisio... NEWPORT BEACH, Calif.-- --Acacia Research Corporation announced today it will release its third quarter financial results on Thursday, October 22, 2009.